Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 Therapeutic DNA Vaccines in Symptomatic HSV-2-Seropositive Adults

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 Therapeutic DNA Vaccines in Symptomatic HSV-2-Seropositive Adults

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Herpes simplex virus DNA vaccine (Primary) ; VCL HM01 (Primary)
  • Indications Herpes genitalis; Herpes simplex virus type 2 infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Vical

    • Most Recent Events

    • 20 Jun 2016 Results from this trial were presented at the American Society of Microbiology (ASM) Microbe/ICAAC 2016 conference, according to a Vical media release.
    • 20 Jun 2016 Results published in a Vical media release.
    • 09 May 2016 Results will be presented at the American Society of Microbiology (ASM) Microbe/ICAAC 2016 conference, according to a Vical media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top